Suresnes (France), January 13th, 2025 – Servier, an independent international pharmaceutical group, announces the appointment of David K. Lee to its Executive Committee as Executive Vice President for the United States, effective January 1, 2025.
David K. Lee has held the position of Chief Executive Officer (CEO) of Servier Pharmaceuticals in the United States since the creation of this subsidiary in 2018. Under his leadership, it has become the Group’s leading entity with five oncology drugs. David K. Lee will continue to lead Servier’s activities in the United States and will contribute, as a member of the Executive Committee, to the definition and implementation of the Group’s global strategy.
David K. Lee holds a degree in biochemistry from Harvard College and an MBA from Harvard Business School. A recognized leader in the pharmaceutical industry, he has held senior positions at Baxalta and Novartis. Before joining Servier, David K. Lee was the Global Head of the Rare Diseases and Oncology franchises at Shire, where he oversaw cross-functional leadership teams responsible for strategy, marketing, business development, R&D, and support functions. He played a key role in Servier’s acquisition of Shire’s oncology portfolio and later the oncology division of Agios.